There is ample evidence that Ang II inhibits the release of acetylcholine (Ach), a neuromediator involved in AD pathology, while the pharmacological inhibition of Ach has been shown to antagonize the detrimental effects of scopolamine on cognitive function. This evidence concerns the gene AGT and Alzheimer disease.